The Angelman Syndrome Foundation Conference will be held in 40 days, we hope to have our data before that date, unlike Phelan Mc Dermid and Pitt Hopkins where behind us there is the desert in Angelman there is a lot competition, primarily Ionis Pharma which will update its study at the conference and Ultragenix which is planning a meeting with the FDA for a possible start of phase 3 by the end of 2024, in the links all the most important studies:
https://www.angelman.org/2024-conference/
https://www.angelman.org/ionis-announces-positive-results-halos/
https://ir.ultragenyx.com/news-rele...orts-first-quarter-2024-financial-results-and
https://www.angelman.org/as-research/clinical-trials/
Angelman trial, page-7
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$16.71 |
Change
-0.590(3.41%) |
Mkt cap ! $2.135B | |||
| Open | High | Low | Value | Volume |
| $17.50 | $17.55 | $16.57 | $10.01M | 594.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 598 | $16.70 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $16.87 | 1676 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| NEU (ASX) Chart |